Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia | Zendy

Richard R. Furman | Zendy; Jeff P. Sharman | Zendy; Steven Coutré | Zendy; Bruce D. Cheson | Zendy; John M. Pagel | Zendy; Peter Hillmen | Zendy; Jacqueline C. Barrientos | Zendy; Andrew D. Zelenetz | Zendy; Thomas J. Kipps | Zendy; Ian W. Flinn | Zendy; Paolo Ghia | Zendy; Herbert Eradat | Zendy; Thomas J. Ervin | Zendy; Nicole Lamanna | Zendy; Bertrand Coiffier | Zendy; Andrew R. Pettitt | Zendy; Shuo Ma | Zendy; Stephan Stilgenbauer | Zendy; Paula Cramer | Zendy; Maria Aiello | Zendy; Dave M. Johnson | Zendy; Langdon L. Miller | Zendy; Daniel Li | Zendy; Thomas M. Jahn | Zendy; Roger Dansey | Zendy; Michael Hallek | Zendy; Susan O’Brien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Author(s) -

Richard R. Furman,

Jeff P. Sharman,

Steven Coutré,

Bruce D. Cheson,

John M. Pagel,

Peter Hillmen,

Jacqueline C. Barrientos,

Andrew D. Zelenetz,

Thomas J. Kipps,

Ian W. Flinn,

Paolo Ghia,

Herbert Eradat,

Thomas J. Ervin,

Nicole Lamanna,

Bertrand Coiffier,

Andrew R. Pettitt,

Shuo Ma,

Stephan Stilgenbauer,

Paula Cramer,

Maria Aiello,

Dave M. Johnson,

Langdon L. Miller,

Daniel Li,

Thomas M. Jahn,

Roger Dansey,

Michael Hallek,

Susan O’Brien

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1315226

Subject(s) - medicine , idelalisib , chronic lymphocytic leukemia , rituximab , ibrutinib , oncology , cd20 , leukemia , population , lymphocytic infiltration , chemotherapy , immunology , lymphoma , environmental health

Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research